PowerUp Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and acquire a business within the interactive media, digital media, sports, entertainment, and/or leisure areas. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2022
Exchange: NASDAQ
SCHEDULE 13G - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)
8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
25-NSE - PowerUp Acquisition Corp. (0001847345) (Subject)
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
425 - PowerUp Acquisition Corp. (0001847345) (Subject)
8-K - PowerUp Acquisition Corp. (0001847345) (Filer)
10-Q - PowerUp Acquisition Corp. (0001847345) (Filer)
10-Q/A - PowerUp Acquisition Corp. (0001847345) (Filer)
10-Q/A - PowerUp Acquisition Corp. (0001847345) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
3 - PowerUp Acquisition Corp. (0001847345) (Issuer)
4 - PowerUp Acquisition Corp. (0001847345) (Issuer)
4 - PowerUp Acquisition Corp. (0001847345) (Issuer)
Fastest customizable press release news feed in the world
Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.Industry-Leading Platform: Aspire is focused on developing a pipeline of products utilizing its novel delivery mechanisms to enhance the efficacy of "do no harm" FDA approved drugs, nutraceuticals and supplements.Innovative Drug Delivery Technology: Aspire's patented and patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs directly into the blood stream, thus on first pass, avoiding the gastrointestinal tract and liver, mitigating unwanted toxicity of this critical organ.Growth and
Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (NASDAQ:PWUP), a Nasdaq Global Market® listed special purpose acquisition company ("PowerUp"), today announced that they have signed a non-binding letter of intent ("LOI") for a potential business combination ("Business Combination"). Under the terms of the LOI, following the consummation of the Business Combination, the combined public company would be listed on a national securities exchange. Aspire Biopharma, Inc. is a privately held, early-stag
New York, NY, June 05, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the "Company") (NASDAQ:PWUP) announced today that, on June 3, 2024, the Company received a notice (the "Notice") from the Nasdaq Listing Qualifications Department ("Nasdaq") indicating that the Company was not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission ("SEC"). The Notice indicates that the Company must, no later than August 2, 2024, submit a plan to regain compliance with respect to the filing requirement. Followi
New York, NY, May 20, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the "Company") (NASDAQ:PWUP) announced today that its extraordinary general meeting of shareholders (the "Meeting"), which was originally scheduled for May 17, 2024 and postponed to May 21, 2024, has been further postponed to 2:00 p.m. Eastern Time, on Wednesday, May 22, 2024. At the Meeting, the Company's shareholders will be asked to vote on a proposal to approve, among other things, extending the date by which the Company must consummate an initial business combination from May 23, 2024 to February 17, 2025. There are no changes to the location, record date, purpose or any of the proposals to be acted upon at the
New York, NY, May 16, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the "Company") (NASDAQ:PWUP) announced today that its extraordinary general meeting of shareholders (the "Meeting"), which was originally scheduled for May 17, 2024, has been postponed to 9:00 a.m. Eastern Time, on Tuesday, May 21, 2024. At the Meeting, the Company's shareholders will be asked to vote on a proposal to approve, among other things, extending the date by which the Company must consummate an initial business combination from May 23, 2024 to February 17, 2025. There are no changes to the location, record date, purpose or any of the proposals to be acted upon at the Meeting. As a result of this change, th
Tarrytown, NY and New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. ("PowerUp") (NASDAQ:PWUP) and Visiox Pharmaceuticals, Inc. ("Visiox"), a commercial-stage biopharmaceutical company, today announced that PowerUp has filed with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 in connection with the previously announced proposed business combination between PowerUp and Visiox (the "Business Combination" or the "Transaction"). The closing of the proposed Business Combination is subject to, among other things, approval by PowerUp's shareholders, satisfaction of the conditions stated in the definitive agreement, and othe
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. ("Visiox" or the "Company"), a commercial-stage biopharmaceutical company, and PowerUp Acquisition Corp. ("PowerUp") (NASDAQ:PWUP) today announced the execution of a definitive agreement for a business combination (the "Transaction" or the "Business Combination") that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market ("Nasdaq"). The business combination is expected to close in the first quarter of 2024, and upon closing the combined company will be named Visiox Holdings, Inc. with its common stock and warrants expected to be listed on Nasdaq under the ticker s
This live feed shows all institutional transactions in real time.
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13D - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)
SC 13G/A - PowerUp Acquisition Corp. (0001847345) (Subject)